Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Oropharyngeal Cancer Pipeline Drugs Market Overview

The Oropharyngeal Cancer pipeline drugs market research report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oropharyngeal Cancer (Oncology) and features dormant and discontinued projects.

Oropharyngeal Cancer Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Oropharyngeal Cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Mast/Stem Cell Growth Factor Receptor Kit, Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, and 5′ Nucleotidase.

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Targets

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Targets

For more Oropharyngeal Cancer pipeline drugs market target insights, download a free report sample

Oropharyngeal Cancer Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanism of actions of the Oropharyngeal Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, 5′ Nucleotidase Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, and Fibroblast Growth Factor Receptor 1 Inhibitor.

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Mechanism of Actions

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Oropharyngeal Cancer pipeline drugs market, download a free report sample

Oropharyngeal Cancer Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Oropharyngeal Cancer pipeline drugs market are intravenous, subcutaneous, oral, intratumor, intravenous drip, parenteral, intravesical, intradermal, intralesional, and intramuscular.

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Routes of Administration

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Oropharyngeal Cancer pipeline drugs market, download a free report sample

Oropharyngeal Cancer Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Oropharyngeal Cancer pipeline drugs market are monoclonal antibody, small molecule, subunit vaccine, recombinant vector vaccine, fusion protein, oncolytic virus, cell therapy, mRNA vaccine, oligonucleotide, and DNA vaccine.

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Molecule Types

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Oropharyngeal Cancer pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Oropharyngeal Cancer pipeline drugs market are AstraZeneca Plc, Incyte Corp, Merck & Co Inc, AbbVie Inc, Boehringer Ingelheim International GmbH, Eisai Co Ltd, Akeso Inc, Hookipa Pharma Inc, Regeneron Pharmaceuticals Inc, and Astex Pharmaceuticals Inc.

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Companies

Oropharyngeal Cancer Pipeline Drugs Market Analysis, by Companies

To know more about the Oropharyngeal Cancer pipeline drugs market companies, download a free report sample

Oropharyngeal Cancer Pipeline Drugs Market Report Overview

Key Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Mast/Stem Cell Growth Factor Receptor Kit, Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, and 5′ Nucleotidase
Key Mechanism of Actions Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, 5′ Nucleotidase Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, and Fibroblast Growth Factor Receptor 1 Inhibitor
Key Routes of Administration Intravenous, Subcutaneous, Oral, Intratumor, Intravenous Drip, Parenteral, Intravesical, Intradermal, Intralesional, and Intramuscular
Key Molecule Types Monoclonal Antibody, Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, Fusion Protein, Oncolytic Virus, Cell Therapy, mRNA Vaccine, Oligonucleotide, and DNA Vaccine
Key Companies AstraZeneca Plc, Incyte Corp, Merck & Co Inc, AbbVie Inc, Boehringer Ingelheim International GmbH, Eisai Co Ltd, Akeso Inc, Hookipa Pharma Inc, Regeneron Pharmaceuticals Inc, and Astex Pharmaceuticals Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
  • Reviews of pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Advaxis Inc
Agenus Inc
Akeso Inc
Anteris Technologies Ltd
Ascenta Therapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aveta Biomics Inc
Bayer AG
BioAtla Inc
Biomimetix JV LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Brooklyn ImmunoTherapeutics Inc
Compugen Ltd
Corvus Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Cue Biopharma Inc
Dracen Pharmaceuticals Inc
Eisai Co Ltd
EpicentRx Inc
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genexine Inc
Genocea Biosciences Inc
GeoVax Labs Inc
Gilead Sciences Inc
GSK plc
Hookipa Pharma Inc
I-Mab
IMV Inc
Incyte Corp
Innovent Biologics Inc
IO Biotech Inc
ISA Pharmaceuticals BV
Jiangsu Hengrui Medicine Co Ltd
Mabpharm Ltd
Merck & Co Inc
Merck KGaA
Moderna Inc
NexImmune Inc
Oncolys BioPharma Inc
Oncorus Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pfizer Inc
Precigen Inc
PsiOxus Therapeutics Ltd
Regeneron Pharmaceuticals Inc
Rubius Therapeutics Inc
Sanofi
Scancell Holdings Plc
Scholar Rock Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shattuck Labs Inc
Syntrix Pharmaceuticals
Tessa Therapeutics Ltd
Theravectys SA
Transcenta Holding Ltd
Transgene SA
Turnstone Biologics Inc
Vaccinex Inc
VasGene Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Oropharyngeal Cancer – Overview

Oropharyngeal Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oropharyngeal Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oropharyngeal Cancer – Companies Involved in Therapeutics Development

Oropharyngeal Cancer – Drug Profiles

Oropharyngeal Cancer – Dormant Projects

Oropharyngeal Cancer – Discontinued Products

Oropharyngeal Cancer – Product Development Milestones

Featured News & Press Releases

Sep 14, 2021: ISA Pharmaceuticals receives Fast Track Designation for lead product ISA101b

Sep 08, 2021: ISA Pharmaceuticals commences patient treatment in third phase 2 clinical trial with the combination of ISA101b and Libtayo (cemiplimab)

Jun 17, 2020: ISA Pharmaceuticals strengthens strategic immuno-oncology collaboration with Regeneron

Oct 14, 2019: ISA Pharmaceuticals receives EUR 20m loan from European Investment Bank

Sep 30, 2019: Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

Jan 22, 2019: ISA Pharmaceuticals randomises first patient in OPC drug trial

Jan 21, 2019: ISA Pharmaceuticals announces start of phase 2 combination trial of ISA101b and Regeneron’s Cemiplimab in oropharyngeal cancer

Dec 20, 2018: Transgene completes safety and tolerability assessment of TG4001 in combination with Avelumab in phase 1b part of trial in HPV-positive cancer patients

Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers

Apr 26, 2018: ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center

Mar 26, 2018: Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers

Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer

Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage

Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Oropharyngeal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Oropharyngeal Cancer – Dormant Projects, 2022

Oropharyngeal Cancer – Dormant Projects, 2022 (Contd..1)

Oropharyngeal Cancer – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Oropharyngeal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets of the Oropharyngeal Cancer pipeline drugs market?

    Some of the key targets of the Oropharyngeal Cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Mast/Stem Cell Growth Factor Receptor Kit, Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, and 5′ Nucleotidase.

  • What are the key mechanism of actions of the Oropharyngeal Cancer pipeline drugs market?

    Some of the key mechanism of actions of the Oropharyngeal Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, 5′ Nucleotidase Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, and Fibroblast Growth Factor Receptor 1 Inhibitor.

  • What are the key routes of administration in the Oropharyngeal Cancer pipeline drugs market?

    The key routes of administration in the Oropharyngeal Cancer pipeline drugs market are intravenous, subcutaneous, oral, intratumor, intravenous drip, parenteral, intravesical, intradermal, intralesional, and intramuscular.

  • What are the key molecule types in the Oropharyngeal Cancer pipeline drugs market?

    The molecule types in the Oropharyngeal Cancer pipeline drugs market are monoclonal antibody, small molecule, subunit vaccine, recombinant vector vaccine, fusion protein, oncolytic virus, cell therapy, mRNA vaccine, oligonucleotide, and DNA vaccine.

  • Which are the key companies in the Oropharyngeal Cancer pipeline drugs market?

    Some of the key companies in the Oropharyngeal Cancer pipeline drugs market are AstraZeneca Plc, Incyte Corp, Merck & Co Inc, AbbVie Inc, Boehringer Ingelheim International GmbH, Eisai Co Ltd, Akeso Inc, Hookipa Pharma Inc, Regeneron Pharmaceuticals Inc, and Astex Pharmaceuticals Inc.

Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.